Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + pirarubicin
- Development stage
- Preclinical
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Gemcitabine + pirarubicin is an experimental combination chemotherapy regimen consisting of two small molecule chemotherapeutic agents, gemcitabine and pirarubicin. Gemcitabine is a nucleoside analog antimetabolite that inhibits DNA synthesis by incorporation into DNA and inhibition of ribonucleotide reductase, leading to cell cycle arrest and apoptosis. Pirarubicin is an anthracycline antibiotic structurally related to doxorubicin; it intercalates into DNA, inhibits topoisomerase II, and generates free radicals, resulting in cytotoxicity primarily through DNA damage. The combination has been investigated for synergistic anti-tumor activity in preclinical models (notably breast cancer) using advanced delivery systems such as pH-responsive polymeric nanoparticles for targeted release within the tumor microenvironment[2][3]. This dual-drug approach aims to maximize efficacy while minimizing toxicity by leveraging complementary mechanisms of action.
- Other names
- pirarubicin and gemcitabine combinationPira-Gem
02
Targets
DNARNR (Ribonucleotide reductase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on gemcitabine + pirarubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + pirarubicin.